258 related articles for article (PubMed ID: 33223508)
21. Histone methyltransferase SETD2 inhibits M1 macrophage polarization and glycolysis by suppressing HIF-1α in sepsis-induced acute lung injury.
Meng Y; Kong KW; Chang YQ; Deng XM; Yang T
Med Microbiol Immunol; 2023 Oct; 212(5):369-379. PubMed ID: 37658121
[TBL] [Abstract][Full Text] [Related]
22. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
23. SETD2, an epigenetic tumor suppressor: a focused review on GI tumor.
Hu M; Hu M; Zhang Q; Lai J; Liu X
Front Biosci (Landmark Ed); 2020 Jan; 25(4):781-797. PubMed ID: 31585917
[TBL] [Abstract][Full Text] [Related]
24. Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.
Li L; Miao W; Huang M; Williams P; Wang Y
Mol Cell Proteomics; 2019 Mar; 18(3):437-447. PubMed ID: 30487242
[TBL] [Abstract][Full Text] [Related]
25. PRMT6 serves an oncogenic role in lung adenocarcinoma via regulating p18.
Tang J; Meng Q; Shi R; Xu Y
Mol Med Rep; 2020 Oct; 22(4):3161-3172. PubMed ID: 32945431
[TBL] [Abstract][Full Text] [Related]
26. Knockdown of SETD2 promotes erastin-induced ferroptosis in ccRCC.
Xue W; Jian W; Meng Y; Wang T; Cai L; Yu Y; Yu Y; Xia Z; Zhang C
Cell Death Dis; 2023 Aug; 14(8):539. PubMed ID: 37604811
[TBL] [Abstract][Full Text] [Related]
27. Agmatinase promotes the lung adenocarcinoma tumorigenesis by activating the NO-MAPKs-PI3K/Akt pathway.
Zhu HE; Yin JY; Chen DX; He S; Chen H
Cell Death Dis; 2019 Nov; 10(11):854. PubMed ID: 31699997
[TBL] [Abstract][Full Text] [Related]
28. Setd2 deficiency impairs hematopoietic stem cell self-renewal and causes malignant transformation.
Zhang YL; Sun JW; Xie YY; Zhou Y; Liu P; Song JC; Xu CH; Wang L; Liu D; Xu AN; Chen Z; Chen SJ; Sun XJ; Huang QH
Cell Res; 2018 Apr; 28(4):476-490. PubMed ID: 29531312
[TBL] [Abstract][Full Text] [Related]
29. LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K/AKT/MYC pathway.
Wei C; Dong X; Lu H; Tong F; Chen L; Zhang R; Dong J; Hu Y; Wu G; Dong X
J Exp Clin Cancer Res; 2019 Feb; 38(1):95. PubMed ID: 30791942
[TBL] [Abstract][Full Text] [Related]
30. SETD2 regulates chromatin accessibility and transcription to suppress lung tumorigenesis.
Xie Y; Sahin M; Wakamatsu T; Inoue-Yamauchi A; Zhao W; Han S; Nargund AM; Yang S; Lyu Y; Hsieh JJ; Leslie CS; Cheng EH
JCI Insight; 2023 Feb; 8(4):. PubMed ID: 36810256
[TBL] [Abstract][Full Text] [Related]
31. Setd2 inactivation sensitizes lung adenocarcinoma to inhibitors of oxidative respiration and mTORC1 signaling.
Walter DM; Gladstein AC; Doerig KR; Natesan R; Baskaran SG; Gudiel AA; Adler KM; Acosta JO; Wallace DC; Asangani IA; Feldser DM
Commun Biol; 2023 Mar; 6(1):255. PubMed ID: 36899051
[TBL] [Abstract][Full Text] [Related]
32. Circular RNA cMras inhibits lung adenocarcinoma progression via modulating miR-567/PTPRG regulatory pathway.
Yu C; Tian F; Liu J; Su M; Wu M; Zhu X; Qian W
Cell Prolif; 2019 May; 52(3):e12610. PubMed ID: 31012177
[TBL] [Abstract][Full Text] [Related]
33. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.
Xie Y; Sahin M; Sinha S; Wang Y; Nargund AM; Lyu Y; Han S; Dong Y; Hsieh JJ; Leslie CS; Cheng EH
Nat Cancer; 2022 Feb; 3(2):188-202. PubMed ID: 35115713
[TBL] [Abstract][Full Text] [Related]
34. miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.
Xiang W; He J; Huang C; Chen L; Tao D; Wu X; Wang M; Luo G; Xiao X; Zeng F; Jiang G
Oncotarget; 2015 Feb; 6(6):4066-79. PubMed ID: 25714014
[TBL] [Abstract][Full Text] [Related]
35. Histone methyltransferase SETD2 modulates alternative splicing to inhibit intestinal tumorigenesis.
Yuan H; Li N; Fu D; Ren J; Hui J; Peng J; Liu Y; Qiu T; Jiang M; Pan Q; Han Y; Wang X; Li Q; Qin J
J Clin Invest; 2017 Sep; 127(9):3375-3391. PubMed ID: 28825595
[TBL] [Abstract][Full Text] [Related]
36. SETD2: an epigenetic modifier with tumor suppressor functionality.
Li J; Duns G; Westers H; Sijmons R; van den Berg A; Kok K
Oncotarget; 2016 Aug; 7(31):50719-50734. PubMed ID: 27191891
[TBL] [Abstract][Full Text] [Related]
37. Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells.
Sheng Y; Ji Z; Zhao H; Wang J; Cheng C; Xu W; Wang X; He Y; Liu K; Li L; Voeltzel T; Maguer-Satta V; Gao WQ; Zhu HH
Cell Prolif; 2019 Jul; 52(4):e12611. PubMed ID: 31054182
[TBL] [Abstract][Full Text] [Related]
38. Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma.
Tiedemann RL; Hlady RA; Hanavan PD; Lake DF; Tibes R; Lee JH; Choi JH; Ho TH; Robertson KD
Oncotarget; 2016 Jan; 7(2):1927-46. PubMed ID: 26646321
[TBL] [Abstract][Full Text] [Related]
39. SETD2 Restricts Prostate Cancer Metastasis by Integrating EZH2 and AMPK Signaling Pathways.
Yuan H; Han Y; Wang X; Li N; Liu Q; Yin Y; Wang H; Pan L; Li L; Song K; Qiu T; Pan Q; Chen Q; Zhang G; Zang Y; Tan M; Zhang J; Li Q; Wang X; Jiang J; Qin J
Cancer Cell; 2020 Sep; 38(3):350-365.e7. PubMed ID: 32619406
[TBL] [Abstract][Full Text] [Related]
40. USF1-induced overexpression of long noncoding RNA WDFY3-AS2 promotes lung adenocarcinoma progression via targeting miR-491-5p/ZNF703 axis.
Ren P; Hong X; Chang L; Xing L; Zhang H
Mol Carcinog; 2020 Aug; 59(8):875-885. PubMed ID: 32275336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]